Evidence map›Paper›PMID 26957369›Full record

ReviewExperimental neurology2016

Intracellular signaling pathway regulation of myelination and remyelination in the CNS.

Jenna M Gaesser, Sharyl L Fyffe-Maricich

Open access · greenAbstract readReview
In one paragraph

Review in Experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 207 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Spinal Cord Injury Remyelination: Pathways to Therapies.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Effects of chemogenetic virus injection and clozapine administration in spinal cord injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  18. Article
  19. Genetic and clinical insights intoFrontiers in pediatrics · 2025
    Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jenna M GaesserDepartment of Pediatrics, Division of Neurology, University of Pittsburgh, Pittsburgh, PA, 15224, United States.
Sharyl L Fyffe-MaricichDepartment of Pediatrics, Division of Neurology, University of Pittsburgh, Pittsburgh, PA, 15224, United States. Electronic address: sharyl.fyffemaricich@chp.edu.
University of Pittsburgh · US

Funding

The role of ERK1/2 MAP kinase signaling in CNS myelinationR01NS091084 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FYFFE-MARICICH, SHARYL LYNNE · 2015 to 2016
$664k
NINDS NIH HHS R01 NS091084
6 · The paper itself

Abstract

The restoration of myelin sheaths on demyelinated axons remains a major obstacle in the treatment of multiple sclerosis (MS). Currently approved therapies work by modulating the immune system to reduce the number and rate of lesion formation but are only partially effective since they are not able to restore lost myelin. In the healthy CNS, myelin continues to be generated throughout life and spontaneous remyelination occurs readily in response to insults. In patients with MS, however, remyelination eventually fails, at least in part as a result of a failure of oligodendrocyte precursor cell (OPC) differentiation and the subsequent production of new myelin. A better understanding of the molecular mechanisms and signaling pathways that drive the process of myelin sheath formation is therefore important in order to speed the development of novel therapeutics designed to target remyelination. Here we review data supporting critical roles for three highly conserved intracellular signaling pathways: Wnt/β-catenin, PI3K/AKT/mTOR, and ERK/MAPK in the regulation of OPC differentiation and myelination both during development and in remyelination. Potential points of crosstalk between the three pathways and important areas for future research are also discussed.

Indexed as

AnimalsCell DifferentiationCentral Nervous SystemDemyelinating DiseasesHumansMyelin SheathNerve RegenerationOligodendrogliaSignal TransductionERK MAPKIntracellular signalingmTORMyelinationOligodendrocyte developmentPI3K/AKTRemyelinationWnt/β-catenin

Identifiers

PMID26957369
PMCPMC5010983
OpenAlexW2292591575

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.